BRPI0416590A - excipientes em veìculos de distribuição de fármacos - Google Patents

excipientes em veìculos de distribuição de fármacos

Info

Publication number
BRPI0416590A
BRPI0416590A BRPI0416590-0A BRPI0416590A BRPI0416590A BR PI0416590 A BRPI0416590 A BR PI0416590A BR PI0416590 A BRPI0416590 A BR PI0416590A BR PI0416590 A BRPI0416590 A BR PI0416590A
Authority
BR
Brazil
Prior art keywords
polymers
excipients
drug delivery
delivery vehicles
gel compositions
Prior art date
Application number
BRPI0416590-0A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0416590A publication Critical patent/BRPI0416590A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"EXCIPIENTES EM VEìCULOS DE DISTRIBUIçãO DE FáRMACOS". A presente invenção fornece composições de gel injetáveis para depósito e kits que fornecem um excipiente para modular uma taxa de liberação e estabilizar os agente benéficos. São fornecidos também métodos para administrar e preparar tais sistemas. As composições do gel compreendem polímeros biodegradáveis, bioerodíveis, e solventes imiscíveis em água, em quantidades eficazes para plastificar os polímeros e formar géis com os polímeros. Os excipientes apropriados incluem modificadores de pH, agentes redutores e antioxidantes.
BRPI0416590-0A 2003-11-14 2004-11-12 excipientes em veìculos de distribuição de fármacos BRPI0416590A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51993603P 2003-11-14 2003-11-14
US10/985,122 US20050106214A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037781 WO2005049069A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (1)

Publication Number Publication Date
BRPI0416590A true BRPI0416590A (pt) 2007-01-30

Family

ID=34576891

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416590-0A BRPI0416590A (pt) 2003-11-14 2004-11-12 excipientes em veìculos de distribuição de fármacos

Country Status (12)

Country Link
US (2) US20050106214A1 (pt)
EP (1) EP1691826A4 (pt)
JP (1) JP4916887B2 (pt)
KR (1) KR20060125749A (pt)
AU (2) AU2004291093A1 (pt)
BR (1) BRPI0416590A (pt)
CA (1) CA2545923A1 (pt)
IL (1) IL175602A0 (pt)
MX (1) MXPA06005463A (pt)
NO (1) NO20062780L (pt)
TW (1) TW200529842A (pt)
WO (1) WO2005049069A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
CA2504608C (en) * 2002-11-06 2013-01-08 Alza Corporation Controlled release depot formulations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007017712A1 (en) * 2005-08-11 2007-02-15 Promedon Do Brasil Produtos Medico-Hospitalares Ltda. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
US7407922B2 (en) * 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP1872807A1 (en) * 2006-06-30 2008-01-02 Scil Technology GmbH Biomaterial containing degradation stabilized polymer
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
KR20150042291A (ko) 2006-10-05 2015-04-20 이카리아 인코포레이티드 액체 칼코게나이드 조성물 및 이의 제조방법과 사용방법
ATE475686T1 (de) * 2006-10-31 2010-08-15 Surmodics Pharmaceuticals Inc Kugelförmige polymer-teilchen
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CN102233129B (zh) * 2010-04-29 2014-07-09 上海交通大学 一种预防或治疗视网膜损伤的长效缓释制剂及其制备方法
EP2590628A1 (en) * 2010-06-30 2013-05-15 Evonik Corporation Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9737605B2 (en) 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
MX2016010328A (es) 2014-02-10 2017-02-06 Hutchinson Fred Cancer Res Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3215223B1 (en) 2014-11-07 2020-07-01 Indivior UK Limited Buprenorphine dosing regimens
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US20170296484A1 (en) * 2015-11-23 2017-10-19 Grace Therapeutics Llc Topical Film-Forming Spray
EP3452031A4 (en) * 2016-05-05 2019-12-11 Liquidia Technologies, Inc. PRECISION-CONTROLLED LOADING AND RELEASE PARTICLES FOR POST-OPERATIONAL PAIN
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109477044B (zh) 2016-07-19 2021-10-08 艺康美国股份有限公司 用于去除口香糖和其它粘性食物的方法和清洁溶液
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
DE69230032T2 (de) * 1991-12-19 2000-02-03 Mitsui Chemicals Inc Polyhydroxycarbonsäure und verfahren zu ihrer herstellung
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
AU668384B2 (en) * 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
DK0959873T3 (da) * 1996-12-20 2006-07-03 Alza Corp Gelsammensætning og fremgangsmåder
RU2184564C2 (ru) * 2000-01-28 2002-07-10 Общество С Ограниченной Ответственностью "Ферон" Лекарственный гель
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US20030027833A1 (en) * 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
BR0206984A (pt) * 2001-11-14 2004-02-03 Alza Corp Composições de depósito injetáveis e uso destas
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
JP2005525403A (ja) * 2002-05-03 2005-08-25 ピーアール ファーマシューティカルズ， インコーポレイテッド エストラジオール代謝産物の徐放性組成物
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
CA2504608C (en) * 2002-11-06 2013-01-08 Alza Corporation Controlled release depot formulations
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
KR20060125749A (ko) 2006-12-06
TW200529842A (en) 2005-09-16
MXPA06005463A (es) 2006-08-11
EP1691826A4 (en) 2012-08-22
US20120177697A1 (en) 2012-07-12
IL175602A0 (en) 2006-09-05
JP4916887B2 (ja) 2012-04-18
WO2005049069A1 (en) 2005-06-02
AU2011201826A1 (en) 2011-05-19
NO20062780L (no) 2006-08-14
CA2545923A1 (en) 2005-06-02
EP1691826A1 (en) 2006-08-23
AU2004291093A1 (en) 2005-06-02
US20050106214A1 (en) 2005-05-19
JP2007511524A (ja) 2007-05-10
AU2011201826B2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
BRPI0416590A (pt) excipientes em veìculos de distribuição de fármacos
BRPI0416032A (pt) excipientes em veìculos de distribuição de fármacos
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
BR0315304A (pt) Formulações com depósito para liberação controlada
BR0313539A (pt) Composições depósito de polìmero multimodais injetáveis e seus usos
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
BR0206984A (pt) Composições de depósito injetáveis e uso destas
MX2009003737A (es) Composicion inyectable en deposito y su procedimiento de preparacion.
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
MA25681A1 (fr) Systeme d'administration de compositions orales de soins comprenant une resine d'organosiloxane utilisant une bandelette de soutien amovible.
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
MX2009002653A (es) Derivados de acido hialuronico obtenidos via reticulacion de "quimica modular".
DE60226282D1 (de) Injizierbare depotzusammensetzungen und deren verwendung
CO6331421A2 (es) Gel de quitosano para aplicaciones dermatologicas proceso de obtencion y uso del mismo
HU230005B1 (en) Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
PL1608346T3 (pl) Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania
ES2195184T3 (es) Preparaciones cosmeticas.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
BR0312033A (pt) Formulações para depósito de curta duração

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.